Lumican is a member of the small-leucine-rich proteoglycan (SLRP) family and is overexpressed during wound healing of the cornea, in ischemic and reperfused heart, and in several cancer tissues. Lumican is considered to regulate the collagen fibril diameter and interfibrillar spacing. However, the effect of lumican on cell growth has not been adequately examined. In the present study, we attempted to clarify whether lumican contributes to human embryonic kidney (HEK) 293 cell growth, using the morpholino antisense oligonucleotide (m-anti oligo) against lumican mRNA. M-anti oligo is a novel oligonucleotide and exhibits a higher antisense activity, higher water solubility, and greater resistance to nucleases in target cells than phosphorothioate types of oligonucleotide. After delivery of m-anti oligo against lumican mRNA, the fluorescein 5-isothiocyanate (FITC) conjugated oligonucleotides were observed in the cytoplasm and nucleus of HEK 293 cells at 24 h by confocal laser microscopy. M-anti oligo for lumican mRNA strongly inhibited the synthesis of lumican protein in the HEK 293 cells, and the HEK cell growth rate was higher than those in the control groups. These findings may indicate that lumican protein has an inhibitory effect on HEK 293 cell growth in vitro.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1827.2004.01593.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research.
Methods Cell Biol
January 2025
Division of Clinical Pharmacology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, A Partnership Between the DKFZ Heidelberg and LMU University Hospital, Munich, Germany; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Electronic address:
Treatment with autologous chimeric antigen receptor (CAR)-modified T cells can achieve outstanding clinical response rates in heavily pretreated patients with B and plasma cell malignancies. However, relapses occur, and they limit the efficacy of this promising treatment approach. The complex GMP-compliant production and high treatment costs cause that CAR T cells cannot yet be used in a broad population.
View Article and Find Full Text PDFA novel and high-performance tumor inhibitor of La, N co-doped carbon dots for U251 and LN229 cells.
Colloids Surf B Biointerfaces
January 2025
Department of Neurosurgery, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University, Ganzhou 341000, China. Electronic address:
To address the medical challenges posed by glioblastoma, a novel and high-performance tumor inhibitor (La@FA-CDs) composed of folic acid and lanthanum nitrate hexahydrate, was successfully synthesized and demonstrated effectiveness in inhibiting the growth of U251 and LN299 cells. The microstructure of La@FA-CDs was extensively analyzed by FTIR, UV-Vis, XPS, TEM, AFM NMR, and nanoparticle size analyzer. The optical and electrical properties of La@FA-CDs were characterized using a fluorescence spectrometer and a zeta potential analyzer.
View Article and Find Full Text PDFPyrimido[5,4-]azolo[1,5-]pyrimidines and pyrimido[4,5-][1,2,4]triazolo[5,1-][1,2,4]triazines: multi-component synthesis and cytotoxic activity.
Org Biomol Chem
January 2025
Ural Federal University named after the First President of Russia B.N. Eltsin, Mira st. 19, Yekaterinburg, 620002, Russian Federation.
A multi-component method for the synthesis of pyrimido[5,4-]azolo[1,5-]pyrimidines and pyrimido[4,5-][1,2,4]triazolo[5,1-][1,2,4]triazines has been developed. It was shown that vicinal amino-nitrile and amino-ethoxycarbonyl derivatives of azolo[1,5-]pyrimidines and azolo[5,1-][1,2,4]triazines were converted to tricyclic heterocycles in the "AcOH-RC(OEt)-amine" system. Reaction conditions were optimized, patterns of this process were investigated, and intermediates were isolated.
View Article and Find Full Text PDFRNA-Targeting CRISPR/CasRx system relieves disease symptoms in Huntington's disease models.
Mol Neurodegener
January 2025
Guangdong Key Laboratory of Non-Human Primate Research, Key Laboratory of CNS Regeneration (Ministry of Education), School of Medicine, GHM Institute of CNS Regeneration, Jinan University, Guangzhou, 510632, China.
Background: HD is a devastating neurodegenerative disorder caused by the expansion of CAG repeats in the HTT. Silencing the expression of mutated proteins is a therapeutic direction to rescue HD patients, and recent advances in gene editing technology such as CRISPR/CasRx have opened up new avenues for therapeutic intervention.
Methods: The CRISPR/CasRx system was employed to target human HTT exon 1, resulting in an efficient knockdown of HTT mRNA.
Blue-LED assisted Photodegradation kinetics of rhodamine-6G dye, enhanced anticancer activity and cleavage of plasmids using Au-ZnO nanocomposite.
Heliyon
January 2025
School of Life Sciences, Department of Biochemistry, Molecular Oncology Laboratory, Bharathidasan University, Tiruchirappalli, 620 024, Tamil Nadu, India.
The plasmonic metal doping on the UV-active metal oxide nanoparticle turns the resultant plasmonic metal-metal oxide (PMMO) into visible light active and upon exogenous illumination the photogenerated energetic charge carriers and the generated reactive oxygen species (ROS, e.g. ·OH and O ) authoritatively enhances its biological and catalytic activity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!